Calm Before The Storm: Pharma Opens 2019 With A Bang In China
Executive Summary
Products old, new and reimbursed were the driving force for foreign drug firms including AstraZeneca, Merck and Pfizer and Sanofi to smash growth in China in the first quarter.
You may also be interested in...
Ready To Ride Next Growth Wave In China? Remember Five Keys
As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.
Pfizer Unveils Upjohn Global HQ In China Amid Unprecedented Pressure On Pricing
In an effort to get closer to customers, Pfizer opens Upjohn global headquarters in Shanghai amid a fast-changing environment, the US-China trade standoff and potentially increased price erosion.
Pfizer Unveils Upjohn Global HQ In China Amid Unprecedented Pricing Pressures
In an effort to get closer to customers, Pfizer opens Upjohn global headquarters in Shanghai amid a fast-changing environment, the US-China trade standoff and potentially increased price erosion.